CN102370638B - Application of 3,3'-diindolylmethane and its derivatives in the preparation of drugs for treating liver diseases - Google Patents

Abstract

The invention belongs to the technical field of biological medicine, specifically relates to an application of diindolylmethane, a precursor compound indole-3-carbinol, and diindolylmethane derivatives in preparation of drugs for treating liver fibrosis, hepatitis and liver cirrhosis-related liver diseases. With the indole-3-carbinol, the diindolylmethane and the diindolylmethane derivatives, thebody can be effectively prevented from damage due to free radical, such that free radical induced stellate cell activation and associated collagen expression are prevented so as to reduce the degree of the liver fibrosis. Therefore, the indole-3-carbinol, the diindolylmethane and the diindolylmethane derivatives can be provided for treating the fibrosis-related liver fibrosis, the hepatitis and the liver cirrhosis diseases.

Description

Application of 3,3'-diindolylmethane and its derivatives in the preparation of drugs for treating liver diseases

1. Technical field

The invention belongs to the technical field of biomedicine, in particular to 3,3'-diindolylmethane (DIM) and its precursor compound indole-3-carbinol (I3C) and their derivative compounds in the preparation and treatment of liver fibrosis and hepatitis , a drug for cirrhosis-associated liver disease. the

2. Background technology

Liver fibrosis refers to the excessive deposition of diffuse extracellular matrix (especially collagen) in the liver. It is not an independent disease. Many chronic liver diseases can cause liver fibrosis. The etiology can be roughly divided into infectious (chronic B, C and D viral hepatitis, schistosomiasis, etc.), congenital metabolic defects ( Hepatolenticular degeneration, hemochromatosis, α1-antitrypsin deficiency, etc.), chemical metabolic defects (chronic alcoholic liver disease, chronic drug-induced liver disease) and autoimmune hepatitis, primary biliary cirrhosis and primary Sclerosing cholangitis, etc. Its clinical symptoms mainly include fatigue, loss of appetite, indigestion, bleeding, etc., and the course of the disease is protracted and may even become cancerous. In the past, the treatment of liver fibrosis mainly focused on glucocorticoids, colchicine, interferon, etc., but the traditional treatment has the disadvantages of unclear targets, large side effects, easy recurrence after drug withdrawal, and high cost. the

In recent years, studies have shown that the occurrence of liver fibrosis is mainly due to the activation of hepatic stellate cells (HSCs), and the activated HSCs can transform into myofibroblasts, one of the important signs of which is the expression of smooth muscle α- Actin (a-SMA), and a large amount of expression and secretion of type I collagen, lead to an imbalance between the synthesis and degradation of the extracellular matrix (extracellular matrix, ECM), resulting in a large amount of extracellular deposition of collagen. Free radicals mainly include superoxide anion radicals (O ₂ ^- ), hydroxyl radicals (OH ^- ), hydrogen peroxide (H ₂ O ₂ ), etc. During the process of liver fibrosis, macrophages in the liver secrete a large amount of Free radicals, the harm of free radicals is that on the one hand, they can directly act on various signaling molecules, promote the proliferation and activation of HSC, and induce the occurrence of liver fibrosis; on the other hand, they can also attack various membrane phase structures of liver cells, causing lipid The peroxidation chain reaction forms a series of lipid peroxides, and lipid peroxidation substances can lead to the formation of liver fibrosis by affecting collagen metabolism. 3,3'-Diindolylmethane (DIM) and its parent compound indole-3-carbinol (I3C) were first reported to have anticancer effects. Indole-3-carbinol (I3C) is very unstable in gastric acid environment in vivo, and can undergo condensation reaction to form oligomer 3,3'-diindolylmethane. Although 3,3'-diindolylmethane has been reported in the literature that it can protect the body from free radical damage, there is no report on its use in the treatment of liver fibrosis and related hepatitis and cirrhosis.

3. Contents of the invention

The problem to be solved by the present invention is to disclose a small molecular compound that can effectively reduce the level of free radicals in the liver, thereby blocking the activation of hepatic stellate cells by free radicals and leading to liver fibrosis, that is, 3,3'-diindole Application of methane and its precursor compound indole-3-carbinol and their derivatives in the preparation of medicines for treating liver fibrosis, hepatitis and liver cirrhosis-related liver diseases. the

Technical scheme of the present invention is:

1. 3 of the present invention, the structural formula of 3 '-diindolylmethane (DIM) and derivatives thereof are:

The R1, R2, R4, R5, R6, R7, R1', R2', R4', R5', R6' and R7' positions of this compound can each be a hydrogen atom, or a group selected from the following groups Substituents, this group includes halogen, nitro, and linear or branched alkane or alkoxy groups with a main chain length of about one to ten carbons and preferably one to five carbons. The above-mentioned compounds have at least one substituent . Halogen is selected from the combination of chlorine, bromine and fluorine. Such compounds are known as DIM derivatives or DIM analogs. the

In the preferred DIM derivatives, R1, R2, R4, R6, R7, R1', R2', R4', R6' and R7' are hydrogen atoms, R5 and R5' are chlorine, bromine, fluorine Halogen selected from the combination. Accordingly, preferred DIM derivatives include 5,5'-dichloro-diindolylmethane; 5,5'-dibromo-diindolylmethane; 5,5'-difluoro-diindolylmethane. Other preferred DIM derivatives include R1, R2, R4, R6, R7, R1', R2', R4', R6' and R7' are hydrogen atoms, R5 and R5' are one to ten carbon atoms preferred one to An alkane or alkoxy compound of five carbon atoms. These compounds include, but are not limited to: 5,5'-dimethyl-diindolylmethane; 5,5'-diethyl-diindolylmethane; 5,5'-dipropyl-diindolylmethane; 5 , 5'-dibutyl-diindolylmethane; 5,5'-dipentyl-diindolylmethane. Other preferred DIM derivatives include R2, R4, R5, R6, R7, R2', R4', R5', R6' and R7' are hydrogen atoms, R1 and R1' are one to ten carbon atoms preferred one to An alkane or alkoxy compound of five carbon atoms. These compounds include, but are not limited to: N,N'-dimethyl-diindolylmethane; N,N'-diethyl-diindolylmethane; N,N'-dipropyl-diindolylmethane; N , N'-dibutyl-diindolylmethane; N,N'-dipentyl-diindolylmethane. Another preferred DIM derivative includes R1, R4, R5, R6, R7, R1', R4', R5', R6' and R7' are hydrogen atoms, and R2 and R2' are preferred for one to ten carbon atoms Alkane or alkoxy compounds of one to five carbon atoms. These compounds include, but are not limited to: 2,2'-dimethyl-diindolylmethane; 2,2'-diethyl-diindolylmethane; 2,2'-dipropyl-diindolylmethane; 2 , 2'-dibutyl-diindolylmethane; 2,2'-dipentyl-diindolylmethane. In another structure, R1, R2, R4, R6, R7, R1', R2', R4', R6' and R7' are hydrogen atoms, and R5 and R5' are nitro groups. the

2. the precursor compound indole-3-carbinol (I3C) of 3 of the present invention, 3'-diindolylmethane and the structural formula of its derivatives are as follows:

The R1, R2, R4, R5, R6, and R7 positions of this compound can each be a hydrogen atom, or a substituent selected from the following groups, which include halogen, nitro, and main chain length About 1 to 10 carbon atoms are preferably 1 to 5 carbon atoms linear or branched chain alkane or alkoxy groups, and the above-mentioned compounds have at least one substituent. the

In the preferred I3C derivative, R1, R2, R4, R6, R7 are hydrogen atoms, and R5 is a halogen selected from chlorine, bromine and fluorine. Accordingly, preferred I3C derivatives include 5-chloro-indole-3-carbinol, 5-bromo-indole-3-carbinol, 5-fluoro-indole-3-carbinol. Other preferred I3C derivatives include R1, R2, R4, R6, and R7 are hydrogen atoms, and R5 is an alkane or alkoxy compound with one to ten carbon atoms, preferably one to five carbon atoms. These compounds include, but are not limited to: 5-methyl-indole-3-carbinol, 5-ethyl-indole-3-carbinol, 5-propyl-indole-3-carbinol, 5-butyl-indole -3-Methanol, 5-pentyl-indole-3-methanol. These compounds also include, but are not limited to: 5-methoxy-indole-3-carbinol, 5-ethoxy-indole-3-carbinol, 5-propoxy-indole-3-carbinol, 5-butane Oxy-indole-3-carbinol, 5-pentyloxy-indole-3-carbinol. Other preferred I3C derivatives include R2, R4, R5, R6, and R7 are hydrogen atoms, and R1 is an alkane or alkoxy compound with one to ten carbon atoms, preferably one to five carbon atoms. These compounds include, but are not limited to: N-methyl-indole-3-carbinol, N-ethyl-indole-3-carbinol, N-propyl-indole-3-carbinol, N-butyl-indole -3-Methanol, N-pentyl-indole-3-methanol. There is also a class of I3C derivatives including R1, R4, R5, R6, and R7 are hydrogen atoms, and R2 is an alkane or alkoxy compound with one to ten carbon atoms, preferably one to five carbon atoms. These compounds include, but are not limited to: 2-methyl-indole-3-carbinol, 2-ethyl-indole-3-carbinol, 2-propyl-indole-3-carbinol, 2-butyl-indole -3-Methanol, 2-pentyl-indole-3-methanol. In another structure, R1, R2, R4, R6, R7 are hydrogen atoms, and R5 is a nitro group. the

3. The medicine in the present invention can be administered through oral cavity, vein, nasal cavity, rectum or any other way that can deliver effective dose of active substance. Suitable dosages are those which give the desired end amount. Different diseases may require different doses. The effective amount of the agent is the amount that can cause a significant reduction in the degree of liver fibrosis. the

A researcher with ordinary skill will be able to determine the most effective dosage and timing of administration of the drugs of the present invention taking into account the mode of administration, drug metabolism, and other pharmacokinetic parameters such as drug distribution, clearance and the like. the

Such drugs can be administered through a drug carrier or diluent. The agents provided by this invention can also be administered in combination with other agents such as chemotherapeutic or immunostimulatory drugs or therapeutic drugs. Examples of pharmaceutical carriers or diluents suitable for this invention include any physiological buffer solution containing a water-soluble organic carrier, such as cyclodextrin phosphate buffer and other buffers containing a suitable water-soluble organic carrier at pH 7.0 to 7.4 liquid. Suitable water-soluble organic carriers include, but are not limited to, cyclodextrin, corn oil, DMSO, capsules, and the like. the

4. The invention is exemplified in vivo on models of liver fibrosis, hepatitis and cirrhosis. The liver fibrosis, hepatitis and liver cirrhosis models used in the present invention are recognized by those skilled in the art as being used to simulate human-related liver fibrosis, viral hepatitis, alcoholic hepatitis, drug-induced hepatitis, fatty liver, and liver cirrhosis The main pathological process of liver diseases. Animals here include but are not limited to: mice, rats, domesticated animals including but not limited to cats, dogs, and other animals such as but not limited to cows, sheep, pigs, horses, primates such as but not limited to monkeys and people. The in vivo detection of the mouse liver fibrosis model is a widely recognized and accepted model for the detection of drug activity in vivo, and can also provide references for other organisms such as humans, but not limited to humans. the

The following example is used to explain the specific details of this invention, but should not be regarded as limiting the functional scope of this invention. the

Application of diindolylmethane, indole-3-carbinol and derivatives thereof in the treatment of liver fibrosis described in the present invention:

1. A phosphate buffered solution of thioacetamide (TAA) was injected intraperitoneally into ICR mice to establish a TAA-type liver fibrosis model. the

2. Dissolve indole-3-carbinol and 3,3'-diindolylmethane and their derivatives in corn oil, and infuse them into the stomach while establishing the TAA-type liver fibrosis model to treat liver fibrosis. the

3. TAA, indole-3-carbinol, 3,3'-diindolylmethane and its derivative compounds were administered twice a week, and the mice were sacrificed after 4 weeks of administration, and the livers were taken out for the determination of hydroxyproline and Alanine aminotransferase assay. the

The application of diindolylmethane and indole-3-carbinol and the aqueous injection preparations of derivatives thereof in the treatment of liver fibrosis model according to the present invention:

1. A phosphate buffered solution of thioacetamide (TAA) was injected intraperitoneally into ICR mice to establish a TAA-type liver fibrosis model. the

2. Inject the prepared aqueous injection preparations of indole-3-carbinol and 3,3'-diindolylmethane and derivatives thereof while establishing the TAA fibrosis model to treat liver fibrosis. the

3. TAA and indole-3-carbinol and 3,3'-diindolylmethane and its derivatives were administered twice a week for 4

The mice were sacrificed one week later, and the livers were taken out for the determination of hydroxyproline and alanine aminotransferase. Application of diindolylmethane and indole-3-carbinol and derivatives thereof in the treatment of hepatitis according to the present invention:

1. The vegetable oil solution of carbon tetrachloride (CC14) was injected intraperitoneally into ICR mice to establish the model of CC14 acute toxic hepatitis. the

2. Dissolve indole-3-carbinol and 3,3'-diindolylmethane and its derivative compounds in corn oil, and infuse them into the stomach while establishing the CC14 type acute toxic hepatitis model to treat hepatitis. the

3. CC14 was administered with indole-3-carbinol, 3,3'-diolylmethane and its derivatives at the same time. The mice were sacrificed 24 hours after the administration, and the serum was taken out for the determination of alanine aminotransferase and aspartate aminotransferase. the

The application of diindolylmethane and indole-3-carbinol and the aqueous solution injection preparations of derivative compounds thereof in the treatment of hepatitis model according to the present invention:

1. The vegetable oil solution of CC14 was injected intraperitoneally into ICR mice to establish the CC14 acute toxic hepatitis model. the

2. The aqueous injection preparations of indole-3-carbinol and 3,3'-diindolylmethane and their derivative compounds prepared are injected while the CC14 type acute toxic hepatitis model is established to treat hepatitis. the

3. CC14 was administered with indole-3-carbinol and 3,3'-diindolylmethane and its derivatives at the same time. The mice were killed 24 hours after administration, and the serum was taken out for the determination of alanine aminotransferase and aspartate aminotransferase. the

Application of diindolylmethane, indole-3-carbinol and derivatives thereof in the treatment of liver cirrhosis model according to the present invention:

1. Use D-galactosamine (DGA) saline solution to inject intraperitoneally into ICR mice to establish a DGA-type liver cirrhosis model. the

2. Dissolve indole-3-carbinol, diindolylmethane and their derivative compounds in corn oil, and infuse them into the stomach while establishing the DGA liver cirrhosis model to treat liver cirrhosis. the

3. DGA was administered simultaneously with indole-3-carbinol, 3,3'-diindolylmethane and its derivatives, 6 times a week, and the mice were sacrificed 6 months after the administration, and the serum was taken out for glutathione Transaminase assay and aspartate aminotransferase assay. the

The application of diindolylmethane, indole-3-carbinol and the aqueous injection preparations of derivatives thereof in the treatment of liver cirrhosis model according to the present invention:

1. Use the normal saline solution of D-galactosamine (DGA) to inject intraperitoneally into ICR mice to establish the DGA-type liver cirrhosis model. the

2. The aqueous injection preparations of indole-3-carbinol and 3,3'-diindolylmethane and their derivative compounds prepared are injected while the DGA liver cirrhosis model is established to treat liver cirrhosis. the

3. DGA was administered simultaneously with indole-3-carbinol, 3,3'-diindolylmethane and its derivatives, 6 times a week, and the mice were sacrificed 6 months after the administration, and the serum was taken out for glutathione Transaminase assay and aspartate aminotransferase assay. the

Compared with the prior art, the present invention has the beneficial effect of providing a new method for treating liver fibrosis by administering 3,3,-diindolylmethane, its precursor compound indole-3-carbinol, and their Derivative compounds and related aqueous injection preparations can protect the body from free radical damage, thereby inhibiting and blocking the onset of liver fibrosis. At the same time, the small molecule drug used in the present invention is easy to obtain, low in price, stable in property, convenient for storage and transportation, and can be prepared as a drug for treating liver diseases related to liver fibrosis, hepatitis and liver cirrhosis. the

4. Specific implementation

1. Preparation of 3,3,-diindolylmethane and indole-3-carbinol and their derivatives

The preparation of 3,3'-diindolylmethane, indole-3-carbinol and derivatives thereof according to the present invention adopts the disclosed conventional synthesis strategy, and the specific experimental conditions refer to the published invention patents (US00594880A, US007348352B2 ). the

Indole derivatives (eg, 5-methoxy, 5-chloro, 5-bromo, 5-fluoro, 5'-methyl, 5-nitro, N-methyl and 2-methylindole) can Commercially available (Nanjing Ruima Fine Chemical Co., Ltd.), the substituted indole-3-acetaldehyde product was obtained by reducing the aldehyde group with a suitable alcohol such as methanol and sodium borohydride to give the I3C substituted derivative. Cool 2.9ml of dimethylformamide to 0°C in an ice-salt bath, and then slowly add 0.86ml of phosphorus oxychloride (more than 30min). Dissolve 8.6mmol of indole derivatives in 1.0ml of dimethylformamide, and then slowly add it to the previously cooled phosphorus oxychloride solution (time greater than 10min), and heat the formed suspension at 37°C for 60min- 90min until the clear yellow solution turns into a yellowish paste. Then 1 ml of ice water was added to the paste, and then 10 ml of an aqueous solution containing 3.75 g of KOH was slowly added (more than 30 min). The mixture was heated to boiling point and cooled. The indole-3-acetaldehyde derivative was obtained by filtration, washed with water, and dried in air. The resulting product was used to prepare derivatives of I3C. the

1.0 g of indole-3-acetaldehyde derivative was dissolved in 5.0 ml of methanol, and solid sodium borohydride was continuously added until all aldehyde groups were reduced. Then 50ml of H ₂ O was added to the reactant, cooled to 0°C, filtered to obtain the I3C derivative, and vacuum-dried in the dark.

1g of I3C derivatives was added to pH5.5 phosphate buffer, stirred at room temperature for 6h, and the whole reaction process was detected by thin layer chromatography (TLC). The DIM derivative was obtained by filtration, dried in vacuum, and placed in a dark place (yield 80%-90%). The yield was confirmed by gas chromatography, liquid chromatography and thin layer chromatography. the

2. Oral administration of 3,3'-diindolylmethane, indole-3-carbinol and their derivatives for the treatment of TAA-induced liver fibrosis in mice

I3C, DIM, and its derivative compounds 5-chloroindole-3-carbinol (5-Cl-I3C), 5,5'-chlorodiindolylmethane (5,5'-Cl-DIM), 2-pentane Indole-3-carbinol (2-C5-I3C), 2,2'-pentyl-diindolylmethane (2,2'-C5-DIM), 5-nitroindole-3-carbinol (5 -NO-I3C), 5,5'-nitrodiindolylmethane (5,5'-NO-DIM), N-methoxyindole-3-methanol (N-MOE-I3C) and N,N '-Methoxy-diindolylmethane (N,N'-MOE-DIM) was dissolved in corn oil and prepared as a 2.0 mg/ml stock solution for later use. According to the method reported in the literature, the TAA liver fibrosis model in mice was established, that is, male ICR mice, weighing 16-18g, were randomly divided into TAA model group, DIM and I3C and their derivatives 5-chloroindole- 3-methanol (5-Cl-I3C), 5,5'-chlorodiindolylmethane (5,5'-Cl-DIM), 2-pentylindole-3-methanol (2-C5-I3C), 2,2'-Pentyl-diindolylmethane (2,2'-C5-DIM), 5-nitroindole-3-carbinol (5-NO-I3C), 5,5'-nitrodiindole Olylmethane (5,5'-NO-DIM), N-methoxyindole-3-carbinol (N-MOE-I3C) and N,N'-methoxy-diindolylmethane (N,N' -MOE-DIM) treatment group, 10 mice per group. Each group of mice was intraperitoneally injected with TAA in phosphate buffer solution (200 mg/kg), twice a week. The treatment started on the week when the model was established. The I3C treatment group, the DIM treatment group, and the 5-methoxy DIM treatment group were intragastrically administered at 20 mg/kg, and the TAA model group was given the corresponding amount of corn oil twice a week. Four weeks after the establishment of the model, they were sacrificed, and the diseased liver tissue was taken for the determination of hydroxyproline and alanine aminotransferase. the

(1) Determination of liver hydroxyproline

The lesioned liver tissue was homogenized and the supernatant was taken, and the content of hydroxyproline was determined by alkaline hydrolysis. the

(2) Liver alanine aminotransferase results

The mouse serum was taken to measure the content of alanine aminotransferase. the

When liver fibrosis occurs, the main increase in the liver is collagen fibers, and hydroxyproline is unique to collagen fibers. Therefore, the content of liver hydroxyproline reflects the degree of liver fibrosis to a certain extent. It can be found from Table 1 that oral administration of I3C, DIM and their derivative compounds can effectively alleviate the onset of liver fibrosis in mice, and the hydroxyproline value in the treatment group was significantly lower than that in the TAA model group. Alanine aminotransferase mainly exists in the plasma of liver cells, and its intracellular concentration is 1000-3000 times higher than that in serum. When liver cells are necrotic, the content of alanine aminotransferase in serum will increase significantly, and liver fibrosis develops to a large number of necrosis of liver cells in the late stage , so it can also be used as an indicator to measure liver fibrosis. It can be seen from Table 1 that after treatment, the alanine aminotransferase value of the treatment group was significantly lower than that of the TAA model group. It can be seen that I3C, DIM and their derivative compounds can significantly reduce liver cell necrosis, delay the onset of liver fibrosis, and reduce disease damage. the

Table 1 Determination of liver hydroxyproline and serum alanine aminotransferase activity

group Hydroxyproline (μg/g liver) Alanine aminotransferase (U/mg protein) model group 356±43 372±24 I3C 237±11* 245±32* DIM 176±21* 204±37* 5-Cl-I3C 220±35* 250±23* 5,5'-Cl-DIM 177±28* 182±13* 2-C5-I3C 266±44* 298±37* 2,2'-C5-DIM 191±30* 205±27* 5-NO-I3C 217±12* 220±17* 5,5'-NO-DIM 146±19* 162±29* N-MOE-I3C 189±23* 200±16* N,N'-MOE-DIM 163±19* 190±21*

The data are displayed in the form of mean ± standard deviation, and significant differences were determined by ANOVA test. the

* represents P≤0.05

3.3,3'-diindolylmethane and indole-3-carbinol and their derivative compounds in the treatment of TAA-induced liver fibrosis model in mice

With reference to the published patent (application number: 2008102435568), I3C, DIM, and its derivative compound 5-chloroindole-3-carbinol (5-Cl-I3C), 5,5'-chlorodiindolylmethane (5, 5'-Cl-DIM), 2-pentylindole-3-carbinol (2-C5-I3C), 2,2'-pentyl-diindolylmethane (2,2'-C5-DIM), 5 -Nitroindole-3-carbinol (5-NO-I3C), 5,5'-nitrodiindolylmethane (5,5'-NO-DIM), N-methoxyindole-3-carbinol (N-MOE-I3C) and N, N'-methoxy-diindolylmethane (N, N'-MOE-DIM) were prepared with cyclodextrin and normal saline to prepare a 1.0 mg/kg stock solution for future use. According to the method reported in the literature, the TAA liver fibrosis model in mice was established, that is, male ICR mice, weighing 16-18g, were randomly divided into TAA model group, DIM and I3C and their derivatives 5-chloroindole- 3-methanol (5-Cl-I3C), 5,5'-chlorodiindolylmethane (5,5'-Cl-DIM), 2-pentylindole-3-methanol (2-C5-I3C), 2,2'-Pentyl-diindolylmethane (2,2'-C5-DIM), 5-nitroindole-3-carbinol (5-NO-I3C), 5,5'-nitrodiindole Olylmethane (5,5'-NO-DIM), N-methoxyindole-3-carbinol (N-MOE-I3C) and N,N'-methoxy-diindolylmethane (N,N' -MOE-DIM) treatment group, 10 mice per group. Each group of mice was intraperitoneally injected with TAA in phosphate buffer solution (200 mg/kg), twice a week. DIM was injected at 20 mg/kg, and the TAA model group was given the same amount of normal saline twice a week. The model was sacrificed four weeks after establishment, and the diseased liver tissue was taken for the determination of hydroxyproline and alanine aminotransferase. See Implementation 1 for the determination of hydroxyproline and alanine aminotransferase. As shown in Table 2, intraperitoneal injection of aqueous solutions of I3C and DIM and its derivative compounds can also slow down the onset of liver fibrosis in mice. the

Table 2 Determination of liver hydroxyproline and serum alanine aminotransferase activity

group Hydroxyproline (μg/g liver) Alanine aminotransferase (U/mg protein) model group 366±33 384±42 I3C 216±12* 221±22* DIM 136±24* 134±27* 5-Cl-I3C 213±24* 230±31* 5,5'-Cl-DIM 167±16* 172±24* 2-C5-I3C 246±42* 268±28*

2,2'-C5-DIM 172±33* 189±17* 5-NO-I3C 205±22* 200±23* 5,5'-NO-DIM 136±29* 142±18* N-MOE-I3C 169±32* 187±26* N,N'-MOE-DIM 153±25* 171±11*

The data are displayed in the form of mean ± standard deviation, and the significant difference is determined by ANOVA test. the

* represents P≤0.05

The above examples are used to explain the specific details of this invention, but should not be regarded as limiting the functional scope of this invention. the

4. Oral administration of 3,3'-diindolylmethane, indole-3-carbinol and their derivatives for the treatment of _CCl4- induced acute toxic hepatitis in mice

I3C, DIM, and its derivative compounds 5-chloroindole-3-carbinol (5-Cl-I3C), 5,5'-chlorodiindolylmethane (5,5'-Cl-DIM), 2-pentane Indole-3-carbinol (2-C5-I3C), 2,2'-pentyl-diindolylmethane (2,2'-C5-DIM), 5-nitroindole-3-carbinol (5 -NO-I3C), 5,5'-nitrodiindolylmethane (5,5'-NO-DIM), N-methoxyindole-3-methanol (N-MOE-I3C) and N,N '-Methoxy-diindolylmethane (N,N'-MOE-DIM) was dissolved in corn oil and prepared as a 2.0 mg/ml stock solution for later use. According to the method reported in the literature, the mouse CCl ₄ hepatitis model was established, that is, male ICR mice, weighing 16-18g, were randomly divided into groups, namely the model group, DIM and I3C and their derivatives 5-chloroindole- 3-methanol (5-Cl-I3C), 5,5'-chlorodiindolylmethane (5,5'-Cl-DIM), 2-pentylindole-3-methanol (2-C5-I3C), 2,2'-Pentyl-diindolylmethane (2,2'-C5-DIM), 5-nitroindole-3-carbinol (5-NO-I3C), 5,5'-nitrodiindole Olylmethane (5,5'-NO-DIM), N-methoxyindole-3-carbinol (N-MOE-I3C) and N,N'-methoxy-diindolylmethane (N,N' -MOE-DIM) treatment group, 10 mice per group. Each group of mice was intraperitoneally injected with 0.12% CCl ₄ peanut oil solution (10ml/kg). Initiate treatment while modeling, DIM and I3C and their derivatives 5-chloroindole-3-carbinol (5-Cl-I3C), 5,5'-chlorodiindolylmethane (5,5'-Cl- DIM), 2-pentylindole-3-carbinol (2-C5-I3C), 2,2'-pentyl-diindolylmethane (2,2'-C5-DIM), 5-nitroindole -3-methanol (5-NO-I3C), 5,5'-nitrodiindolylmethane (5,5'-NO-DIM), N-methoxyindole-3-methanol (N-MOE- I3C) and N, N'-methoxyl-diindolylmethane (N, N'-MOE-DIM) were administered orally at 20 mg/kg, and the CCl ₄ model group was given a corresponding amount of corn oil. The model was sacrificed 24 hours after establishment, and the serum of the mice was collected to measure alanine aminotransferase and aspartate aminotransferase.

ALT and AST mainly exist in liver cells, and their intracellular concentration is 1000-3000 times higher than that in serum. When liver cells are necrotic, the levels of ALT and AST in serum will increase significantly. However, in the mouse model of acute toxic hepatitis induced by CCl ₄ , a large number of liver cells are necrotic, so it can be used as an index to measure the severity of hepatitis. It can be seen from Table 3 that after treatment, the values of alanine aminotransferase and aspartate aminotransferase in the treatment group were significantly lower than those in the CCl ₄ model group. It can be seen that I3C, DIM and their derivative compounds can significantly reduce liver cell necrosis, alleviate hepatitis, and reduce disease damage.

Table 3 Determination of alanine aminotransferase and aspartate aminotransferase activity in serum

The data are displayed in the form of mean ± standard deviation, and the significant difference is determined by ANOVA test. the

* represents P≤0.05

5.3, 3'-diindolylmethane and indole-3-carbinol and its derivative compounds aqueous injection preparations for the treatment of CCl ₄ induced acute toxic hepatitis model in mice

With reference to the published patent (application number: 2008102435568), I3C, DIM, and its derivative compound 5-chloroindole-3-carbinol (5-Cl-I3C), 5,5'-chlorodiindolylmethane (5, 5'-Cl-DIM), 2-pentylindole-3-carbinol (2-C5-I3C), 2,2'-pentyl-diindolylmethane (2,2'-C5-DIM), 5 -Nitroindole-3-carbinol (5-NO-I3C), 5,5'-nitrodiindolylmethane (5,5'-NO-DIM), N-methoxyindole-3-carbinol (N-MOE-I3C) and N, N'-methoxy-diindolylmethane (N, N'-MOE-DIM) were prepared with cyclodextrin and normal saline to prepare a 1.0 mg/kg stock solution for future use. The mouse _CCl4 liver fibrosis model was established with reference to Implementation 4. On the day of modeling, the mice were randomly divided into model groups, DIM and I3C and their derivatives 5-chloroindole-3-carbinol (5-Cl- I3C), 5,5'-chlorodiindolylmethane (5,5'-Cl-DIM), 2-pentylindole-3-carbinol (2-C5-I3C), 2,2'-pentyl- Diindolylmethane (2,2'-C5-DIM), 5-nitroindole-3-methanol (5-NO-I3C), 5,5'-nitrodiindolylmethane (5,5'- NO-DIM), N-methoxyindole-3-carbinol (N-MOE-I3C) and N,N'-methoxy-diindolylmethane (N,N'-MOE-DIM) treatment groups , 10 mice per group. Start treatment while establishing the model, I3C, DIM, and its derivative compounds 5-chloroindole-3-carbinol (5-Cl-I3C), 5,5'-chlorodiindolylmethane (5,5'-Cl- DIM), 2-pentylindole-3-carbinol (2-C5-I3C), 2,2'-pentyl-diindolylmethane (2,2'-C5-DIM), 5-nitroindole -3-methanol (5-NO-I3C), 5,5'-nitrodiindolylmethane (5,5'-NO-DIM), N-methoxyindole-3-methanol (N-MOE- I3C) and N, N'-methoxyl-diindolylmethane (N, N'-MOE-DIM) treatment groups were injected with DIM at 20 mg/kg, and the CCl4 model group was given a corresponding amount of normal saline. The model was sacrificed 24 hours after establishment, and the serum of the mice was collected to measure alanine aminotransferase and aspartate aminotransferase. Determination of alanine aminotransferase and aspartate aminotransferase see

Implementation 4

As shown in Table 3, intraperitoneal injection of aqueous solution injection preparations of I3C and DIM and its derivative compounds can also reduce the degree of hepatitis attack in mice. the

Table 4 Determination of alanine aminotransferase and aspartate aminotransferase activity in serum

The data are displayed in the form of mean ± standard deviation, and the significant difference is determined by ANOVA test. the

* represents P≤0.05

6.3,3'-Diindolylmethane and indole-3-carbinol and their derivatives for the treatment of DGA-induced liver cirrhosis in mice

I3C, DIM, and its derivative compounds 5-chloroindole-3-carbinol (5-Cl-I3C), 5,5'-chlorodiindolylmethane (5,5'-Cl-DIM), 2-pentane Indole-3-carbinol (2-C5-I3C), 2,2'-pentyl-diindolylmethane (2,2'-C5-DIM), 5-nitroindole-3-carbinol (5 -NO-I3C), 5,5'-nitrodiindolylmethane (5,5'-NO-DIM), N-methoxyindole-3-methanol (N-MOE-I3C) and N,N '-Methoxy-diindolylmethane (N,N'-MOE-DIM) was dissolved in corn oil and prepared as a 2.0 mg/ml stock solution for later use. According to the method reported in the literature, the mouse DGA liver cirrhosis model was established, that is, the male ICR mice weighing 16-18g were taken, and the mice were randomly divided into groups, namely the model group, DIM and I3C and their derivatives 5-chloroindole- 3-methanol (5-Cl-I3C), 5,5'-chlorodiindolylmethane (5,5'-Cl-DIM), 2-pentylindole-3-methanol (2-C5-I3C), 2,2'-Pentyl-diindolylmethane (2,2'-C5-DIM), 5-nitroindole-3-carbinol (5-NO-I3C), 5,5'-nitrodiindole Olylmethane (5,5'-NO-DIM), N-methoxyindole-3-carbinol (N-MOE-I3C) and N,N'-methoxy-diindolylmethane (N,N' -MOE-DIM) treatment group, 10 mice per group. Each group of mice was intraperitoneally injected with 10% DGA in normal saline solution (250 mg/kg). Start treatment while establishing the model, I3C, DIM, and its derivative compounds 5-chloroindole-3-carbinol (5-Cl-I3C), 5,5'-chlorodiindolylmethane (5,5'-Cl- DIM), 2-pentylindole-3-carbinol (2-C5-I3C), 2,2'-pentyl-diindolylmethane (2,2'-C5-DIM), 5-nitroindole -3-methanol (5-NO-I3C), 5,5'-nitrodiindolylmethane (5,5'-NO-DIM), N-methoxyindole-3-methanol (N-MOE- I3C) and N, N'-methoxyl-diindolylmethane (N, N'-MOE-DIM) treatment group was administered by intragastric administration at 20 mg/kg, and the DGA model group was given a corresponding amount of corn oil, given weekly Medicine 6 times. The model was sacrificed 6 months after establishment, and the serum of the mice was collected to measure alanine aminotransferase and aspartate aminotransferase. the

ALT and AST mainly exist in liver cells, and their intracellular concentration is 1000-3000 times higher than that in serum. When liver cells are necrotic, the levels of ALT and AST in serum will increase significantly. After DGA enters the body, it can cause the capture of guanosine triphosphate in the liver, the synthesis of glycogen, RNA, and glycoprotein, the exhaustion of glutathione, the activation of hepatic macrophages, and the massive release of TNF-a, which will lead to liver damage. Cell functional and structural damage, and induce liver tissue necrosis and liver cell apoptosis, so alanine aminotransferase and aspartate aminotransferase can be used as indicators to measure the severity of liver cirrhosis. It can be seen from Table 5 that after treatment, the values of alanine aminotransferase and aspartate aminotransferase in the treatment group were significantly lower than those in the DGA model group. It can be seen that I3C, DIM and their derivative compounds can significantly reduce liver cell necrosis, delay the onset of liver cirrhosis, and reduce disease damage. the

Table 5 Determination of alanine aminotransferase and aspartate aminotransferase activity in serum

The data are displayed in the form of mean ± standard deviation, and the significant difference is determined by ANOVA test. the

* represents P≤0.05

7.3, 3'-diindolylmethane and indole-3-carbinol and their derivative compounds in the treatment of DGA-induced liver cirrhosis in mice

With reference to the published patent (application number: 2008102435568), I3C, DIM, and its derivative compound 5-chloroindole-3-carbinol (5-Cl-I3C), 5,5'-chlorodiindolylmethane (5, 5'-Cl-DIM), 2-pentylindole-3-carbinol (2-C5-I3C), 2,2'-pentyl-diindolylmethane (2,2'-C5-DIM), 5 -Nitroindole-3-carbinol (5-NO-I3C), 5,5'-nitrodiindolylmethane (5,5'-NO-DIM), N-methoxyindole-3-carbinol (N-MOE-I3C) and N, N'-methoxy-diindolylmethane (N, N'-MOE-DIM) were prepared with cyclodextrin and normal saline to prepare a 1.0 mg/kg stock solution for future use. The mouse DGA liver cirrhosis model was established with reference to Implementation 6. On the day of modeling, the mice were randomly divided into model groups, DIM and I3C and their derivatives 5-chloroindole-3-carbinol (5-Cl-I3C) , 5,5'-chlorodiindolylmethane (5,5'-Cl-DIM), 2-pentylindole-3-carbinol (2-C5-I3C), 2,2'-pentyl-diindole Olylmethane (2,2'-C5-DIM), 5-nitroindole-3-carbinol (5-NO-I3C), 5,5'-nitrodiindolylmethane (5,5'-NO- DIM), N-methoxyindole-3-carbinol (N-MOE-I3C) and N, N'-methoxy-diindolylmethane (N, N'-MOE-DIM) treatment groups, each Group 10 mice. Initiate treatment while modeling, DIM and I3C and their derivatives 5-chloroindole-3-carbinol (5-Cl-I3C), 5,5'-chlorodiindolylmethane (5,5'-Cl- DIM), 2-pentylindole-3-carbinol (2-C5-I3C), 2,2'-pentyl-diindolylmethane (2,2'-C5-DIM), 5-nitroindole -3-methanol (5-NO-I3C), 5,5'-nitrodiindolylmethane (5,5'-NO-DIM), N-methoxyindole-3-methanol (N-MOE- I3C) and N, N'-methoxyl-diindolylmethane (N, N'-MOE-DIM) treatment group was injected with DIM at 20 mg/kg, and the DGA model group was given a corresponding amount of normal saline, administered weekly 6 times. The model was sacrificed 6 months after establishment, and the serum of the mice was collected to measure alanine aminotransferase and aspartate aminotransferase. Determination of alanine aminotransferase and aspartate aminotransferase see implementation 4

As shown in Table 6, intraperitoneal injection of aqueous solution injection preparations of I3C and DIM and its derivative compounds can also delay the onset of liver cirrhosis in mice. the

Table 6 Determination of alanine aminotransferase and aspartate aminotransferase activity in serum

The data are displayed in the form of mean ± standard deviation, and the significant difference is determined by ANOVA test. the

* represents P ≤ 0.05. the

Claims (2)

1. micromolecular compound 3, the derivant of 3 '-di-indole methyl hydride: 5,5 '-two chloro-di-indole methyl hydrides or 5,5 '-diamyl-di-indole methyl hydride or 5,5 '-dinitro-di-indole methyl hydride or N, the application of N '-dimethoxy-di-indole methyl hydride in preparation treatment hepatic fibrosis or liver cirrhosis medicine.

2. the according to claim 1 application of the derivant of described micromolecular compound 3,3'-Diindolylmethane is characterized in that hydrous water dissolubility organic carrier cyclodextrin or Semen Maydis oil or dimethyl sulfoxide.